Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian C Betts

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Transplantation and Cellular Therapy|December 15, 2025
HIGHER HLA-DRB1 EVOLUTIONARY DIVERGENCE (HED) IS ASSOCIATED WITH REDUCED RELAPSE AND IMPROVED SURVIVAL AFTER MATCHED UNRELATED HEMATOPOIETIC CELL TRANSPLANTATIONJennifer N Saultz, Yung-Tsi Bolon, Tao Wang, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/MethotrexateNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
Haematologica|June 13, 2012
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationJoseph Pidala, Jongphil Kim, Heather Jim, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2018
Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiationBrian C Betts, David Bastian, Supinya Iamsawat, et al.
Haematologica|January 21, 2017
IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantationBrian C Betts, Joseph Pidala, Jongphil Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2017
Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory StudyHemant S Murthy, Kyle Sheets, Ambuj Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial ResultsJoseph Pidala, Kelly Walton, Hany Elmariah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict MortalityShernan G Holtan, Constanza Savid-Frontera, Kelly Walton, et al.
Transplantation and Cellular Therapy|June 13, 2023
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate MofetilNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
Blood|July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial resultsJoseph Pidala, Shernan G Holtan, Kelly Walton, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Transplantation and Cellular Therapy|December 15, 2025
HIGHER HLA-DRB1 EVOLUTIONARY DIVERGENCE (HED) IS ASSOCIATED WITH REDUCED RELAPSE AND IMPROVED SURVIVAL AFTER MATCHED UNRELATED HEMATOPOIETIC CELL TRANSPLANTATIONJennifer N Saultz, Yung-Tsi Bolon, Tao Wang, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/MethotrexateNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
Haematologica|June 13, 2012
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationJoseph Pidala, Jongphil Kim, Heather Jim, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2018
Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiationBrian C Betts, David Bastian, Supinya Iamsawat, et al.
Haematologica|January 21, 2017
IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantationBrian C Betts, Joseph Pidala, Jongphil Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2017
Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory StudyHemant S Murthy, Kyle Sheets, Ambuj Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial ResultsJoseph Pidala, Kelly Walton, Hany Elmariah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict MortalityShernan G Holtan, Constanza Savid-Frontera, Kelly Walton, et al.
Transplantation and Cellular Therapy|June 13, 2023
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate MofetilNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
Blood|July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial resultsJoseph Pidala, Shernan G Holtan, Kelly Walton, et al.
Pageof 6